Showing 1-10 of 477 results for "".
SDPA: Dr. Matthew Zirwas Discusses Benefits of Attending the Annual Conference
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-matthew-zirwas-discusses-benefits-of-attending-the-annual-conference/29510/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Matthew Zirwas, MD. Dr. Zirwas shares why he looks forward to lecturing at the annual meeting.Clinical Insights and Emerging Therapeutic Options for Chronic Hand Eczema
https://practicaldermatology.com/issues/october-2025/clinical-insights-and-emerging-therapeutic-options-for-chronic-hand-eczema/39763/Chronic hand eczema (CHE) represents a significant clinical challenge in dermatology practice, affecting approximately 5% of the population—a prevalence approximately twice that of psoriasis.Eczematous Dermatitis: Dr. Zirwas
https://practicaldermatology.com/programs/practical-dermatology/eczematous-dermatitis-dr-zirwas/32689/Matthew Zirwas, MD, talks about the therapeutic strategies for non-atopic dermatitis—particularly hand dermatitis and facial dermatitis—that he covered during "Eczematous Dermatitis Update 2025: Contact, Hand, Head and Neck, Eyelid and More" at Maui Derm 2025.SDPA: Dr. Matthew Zirwas Shares Passion for Treating Atopic Dermatitis
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-matthew-zirwas-shares-passion-for-treating-atopic-dermatitis/29509/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Matthew Zirwas, MD. He provides a passionate overview of his lecture on atopic dermatitis, itch, and contact dermatitis.Analyzing Safety Data From Level Up
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuISDPA: Dr. Bhatia and Dr. Zirwas Discuss the Itchy Patient
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-and-dr-zirwas-discuss-itchy-patient/27065/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks with Matthew Zirwas, MD, about Dr. Zirwas’s lecture on the itchy patient and the latest solutions for itch at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.A Closer Look at OX40 Pathway Modulation
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/a-closer-look-at-ox40-pathway-modulation/50890/Walter Liszewski, MD, talks with Matthew Zirwas, MD, about the potential therapeutic applications, based on the article “Targeting the OX40-OX40L pathway: A new era in atopic dermatitis management by T-cell rebalancing,”1 as well as the risks of therapies targeting the OX40 pathway.From SDPA: JAKs, Black Boxes, and What It All Means
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-jaks-black-boxes-and-what-it-all-means/26286/Practitioners shouldn’t fear Janus kinase (JAK) inhibitors for their patients when appropriate, according to a wide-ranging expert chat at the 2024 SDPA Annual Summer Conference in San Diego. The conversation featured Matthew Zirwas, MD, a dermatologist with DOCS Dermatology, and Amy Spizuoco, DO, FCSF After Dark
https://practicaldermatology.com/topics/practice-management/csf-after-dark/20404/What happens in Vegas stays in Vegas. Or does it?Controversies to Take Center Stage at CSF
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/controversies-to-take-center-stage-at-csf/20340/A new venue and new speakers—and a focus on hot topics—will be part of CSF 2018.
- Prev
- Next